Zimmer Biomet Holdings (ZBH) has had a mixed performance in recent events. The company's Q1 earnings rose, leading them to revise their 2025 revenue guidance upward, and they reported better-than-expected sales. They also completed the acquisition of Paragon 28 and are focusing on launching new products for knee growth. ZBH has seen some setbacks with price target cuts and shares plummeting following disappointing Q1 results. There is concern among analysts about ZBH's future growth prospects, with some lowering their forecasts. Despite this, the company retains an outperform rating. EPS beat expectations in Q1 2025 earnings, but they have had to narrow their 2025 EPS guidance range and lower their 2025 profit forecast due to tariff uncertainty. While results are mixed, the company is making strategic moves and looking to innovate with robust Q1 performance and reaffirmation of its dividend. However, uncertainty remains with some analysts recommending a cautious hold on the stock.
Zimmer Biomet Holdings ZBH News Analytics from Sat, 16 Nov 2024 08:00:00 GMT to Fri, 09 May 2025 11:44:40 GMT -
Rating -2
- Innovation 3
- Information 5
- Rumor -5
